In these tepid times for biotech, the IPO market has become the industry’s own Punxsutawney, Penn., where a prolonged dry spell has led finicky investors to see each new offering as either a sign of bullish times to come or an ominous extension of bearish winter.
And with three biotech upstarts expected to make their Wall Street debuts this week, there’s plenty opportunity for shifts in the narrative. Here’s a look at the companies angling to go public in the coming days.
About the Author Reprints
